Abstract
Tumor necrosis factor (TNF) was first described in 1975 [1] as a soluble factor appearing in the serum of mice treated with BCG and endotoxin. This factor received its name because it caused the hemorrhagic necrosis of a transplantable sarcoma in mice. Subsequently, TNF was found to be a protein secreted by activated macrophages and was described in virtually all vertebrate animals, including humans. TNF was purified and the gene for human TNF was cloned and expressed in bacteria, making available large quantities of purified recombinant human TNF (rTNF) [2–4].
Keywords
- Tumor Necrosis Factor
- L929 Cell
- Superficial Bladder Cancer
- Human Tumor Necrosis Factor
- Hemorrhagic Necrosis
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Carswell EA, Old LJ, Kasel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA, 72:3666–3670,1975.
Pennica D, Hayfiick JS, Bringman TS, Palladino MA, Goeddel DV: Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci USA, 82:6060–6064, 1985.
Wang AM, Creasey AA, Ladner MB, Lin LS, Strickler J, Van Arsdell JN, Yamamoto R, Mark DF: Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 228:149–154, 1985.
Shirai T, Yamaguchi H, Ito H, Todd CW, Wallace RB: Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Nature 313:803–806, 1985.
Alexander RB, Rosenberg SA: Tumor necrosis factor: Clinical applications. In: DeVita VT, Hellman S, Rosenberg SA (eds). Biologic Therapy of Cancer: Principles and Practice. J.B. Lippincott, Philadelphia, 1990.
Mclntosh JK, Mulé JJ, Merino MJ, Rosenberg SA: Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha. Cancer Res 48:4011–4017, 1988.
Stone-Wolff DS, Yip YK, Kelker HC, Le J, Henriksen-Destefano D, Rubin BY, Rinderknecht E, Aggarwal BB, Vilcěk J: Interrelationships of human interferon-gamma with lymphotoxin and monocyte cytotoxin. J Exp Med 159:828–843, 1984.
Aggarwal BB, Eessalu TE, Hass PE: Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature 318:665–667, 1985.
Kavoussi LR, Ruesing RA, Hudson MA, Catalona WJ, Ratliff TL: Effect of tumor necrosis factor and interferon gamma on human renal carcinoma cell line growth. J Urol 142:875–878, 1989.
Mclntosh JK, Mulé JJ, Krosnick JA, Rosenberg SA: Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice. Cancer Res 49:1408–1414, 1989.
Ruff MR, Gifford GE: Tumor necrosis factor. In: Pick E (ed). Lymphokines, Vol. 2. Academic Press, New York, 1981, pp. 235–271.
Alexander RB, Nelson WG, Coffey DS: Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res 47:2403–2406, 1987.
Alexander RB, Isaacs JT, Coffey DS: Tumor necrosis factor enhances the in vitro and in vivo efficacy of chemotherapeutic drugs targeted at DNA topoisomerase II in the treatment of murine bladder cancer. J Urol 138:427–429, 1987.
Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cortran RS, Gimbrone MA, Jr.: Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 83:4533–4537, 1986.
Stolpen AH, Guinan EC, Fiers W, Pober JS: Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am J Pathol 123:16–24, 1986.
Tennenberg SD, Solomkin JS: Activation of neutrophils by cachectin/tumor necrosis factor: Priming of N-formyl-methionyl-leucyl-phenylalanine-induced oxidative responsiveness via receptor mobilization without degranulation. J Leuk Biol 47:217–223, 1990.
Beutler B, Milsark IW, Cerami AC: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869–871, 1985.
Michie HR, Manogue KR, Spriggs DR, Revhaug A, O’Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481–1486, 1988.
Levine B, Kaiman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heat failure. N Engl J Med 323:236–241, 1990.
Rook GAW, Taverne J, Moreno C: The role of tumor necrosis factor in the pathogenesis of tuberculosis and leprosy and the relationship between tissue-damaging pathology and production of agalactosyl IgG. In: Bonavida B, Granger G (eds). Tumor Necrosis Factor: Structure, Mechanism of Action, Role in Disease and Therapy. Karger, Basel, 1990, pp. 168-176.
Creasey AA, Reynolds MT, Laird W: Cures and Partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res 46:5687–5690, 1986.
Mulé JJ, Asher A, McIntosh J, Lafreniere R, Shiloni E, Lefor A, Reichert CM, Rosenberg SA: Antitumor effect of recombinant tumor necrosis factor-alpha against murine sarcomas at visceral sites: Tumor size influences the response to therapy. Cancer Immunol Immunother 26:202–208, 1988.
Mclntosh JK, Mulé JJ, Travis WD, Rosenberg SA: Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice. Cancer Res 50:2463–2469, 1990.
Asher AL, Mulé JJ, Rosenberg SA: Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells. Cancer Immunol Immunother 28:153–156, 1989.
Havell EA, Fiers W, North RJ: The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med 167:1067–1085, 1988.
Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Jr., Shepard HM: Recombinant human tumor necrosis factor-alpha: Effects on proliferation of normal and transformed cells in vitro. Science 230:943–945, 1985.
Ostrove JM, Gifford GE: Stimulation of RNA synthesis in L929 cells by rabbit tumor necrosis factor. Proc Soc Exp Biol Med 160:354–358, 1979.
Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF: Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466–468, 1984.
Liu LF: DNA topoisomerases — enzymes that catalyze the breaking and rejoining of DNA. CRC Crit Rev Biochem 15:1–24, 1983.
D’Arpa P, Liu LF: Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 989: 163–177, 1989.
Pienta KJ, Partin AW, Coffey DS: Cancer as a disease of DNA organization and dynamic cell structure. Cancer Res 49:2525–2532, 1989.
Fruehauf JP, Myers CE, Sinha BK: Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer cell lines. J Natl Cancer Inst 82:1206–1209, 1990.
Bahnson RR, Ratliff TL: In vitro and in vivo anti-tumor activity of recombinant mouse tumor necrosis factor (TNF) in a mouse bladder tumor (MBT-2). J Urol 144:172–175, 1990.
Gapany M, Dawson DE, Schriever C, Burgess R, Gipple JR, Riggs CE, Jr.: Tumor necrosis factor and cytotoxic agents. Effect on squamous carcinoma lines. Arch Otolaryngol Head Neck Surg 116: 436–439,1990.
Giaccone G, Kadoyama C, Maneckjee R, Venzon D, Alexander RB, Gazdar AF: Effects of tumor necrosis factor, alone or in combination with topoisomerase-II-targeted drugs, on human lung cancer cell lines. Int J Cancer 46:326–329, 1990.
Iizumi T, Yazaki T, Waku M, Soma G: Immunochemotherapy for murine bladder tumor with a new human recombinant tumor necrosis factor (rTNF-S), VP-16 and hyperthermia. J Urol 142:386–389, 1989.
Krosnick JA, Mule JJ, Mclntosh JK, Rosenberg SA: Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res 49:3729–3733, 1989.
Bloom ND, Norbergs DA, Sherman B, Sadjadi M, Ramaswamy G, Jacobs R, Ackerman N: Augmentation of the effect of doxorubicin with low-dose tumor necrosis factor in experimental liver metastasis. Mol Biother 2:121–124, 1990.
Das AK, Walther PJ, Buckley NJ, Poulton SH: Recombinant human tumor necrosis factor alone and with chemotherapeutic agents. Effect on nude mouse-supported human bladder cancer heterografts. Arch Surg 124:107–110, 1989.
Donaldson JT, Keane TE, Poulton SH, Walther PJ: Enhanced in vivo cytotoxicity of recombinant human tumor necrosis factor with etoposide in human renal cell carcinoma. Evaluation in a pre-clinical model. Urol Res 18:245–250, 1990.
Burgers JK, Marshall FF, Isaacs JT: Enhanced anti-tumor effects of recombinant human tumor necrosis factor plus VP-16 on metastatic renal cell carcinoma in a xenograft model. J Urol 142:160–164, 1989.
Schmid DS, Hornung R, McGrath KM, Paul N, Ruddle NH: Target cell DNA fragmentation is mediated by lymphotoxin and tumor necrosis factor. Lymphokine Res 6: 195–202, 1987.
Kyprianou N, English HF, Isaacs JT: Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50:3748–3753, 1990.
Rubin BY, Anderson SL, Lunn RM, Hellermann GR, Smith LJ: Fragmentation of cellular DNA is a nonspecific indicator of responsiveness to tumor necrosis factor. J Biol Response Mod 8:553–559, 1989.
Kyprianou N, Alexander RB, Isaacs JT: Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II targeted drugs in L929 cells. J Natl Cancer Inst 83:346–350, 1991.
Utsugi T, Mattern MR, Mirabelli CK, Hanna N: Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: Enhancement of topoisomerase activity as a mechanism of potentiation. Cancer Res 50:2636–2640, 1990.
Taylor C, Hersh E, Plezia P, Alberts D, McCloskey T, Wiggins C, Ahmann F, King D, Rudolph A: A phase I and pharmacokinetic study of recombinant tumor necrosis factor and doxorubicin (abstr.). Proc Am Soc Clin Oncol 8:183–183, 1989.
Orr D, Oldham R, Lewis M, Bertoli L, Birch R: Phase I study of the sequenced administration of etoposide and recombinant tumor necrosis factor in patients with advanced malignancy (Abstr.). Proc Am Soc Clin Oncol 8:190–190, 1989.
Simons JW, Rowinsky EK, McGuire WP, Fornastiere AA, Nelson WG, Ettinger DS, Grochow LB, Clarke BV, Lubejko BG, Duerr MT, Burgers JK, Marshall FF, Donehower RG: Phase I study of overlapping continuous infusion VP-16 and recombinant human tumor necrosis factor in advanced cancer (Abstr.). Proc Am Soc Clin Oncol 9:200–200, 1990.
Riggs CE, Davis RT, Ratain MJ, Schilsky R, Vogelzang NJ, Geick J, Jarnow L, O’Brien S, Denger P: Pharmacokinetics of adriamycin in combination with human tumor necrosis factor. Results from a phase I trial (Abstr.). Proc Am Assoc Cancer Res 31:179–179, 1990.
Kahn JO, Kaplan LD, Volberding PA, Ziegler JL, Crowe S, Saks SR, Abrams DI: Intralesional recombinant tumor necrosis factor-alpha for AIDS-associated Kaposi’s sarcoma: A randomized, double-blind trial. J Acquir Immune Defic Syndr 2:217–223, 1989.
Bahnson RR, Ballou BT, Ernstoff MS, Cramer DV, Schwentker FN, Reiland JM, Hakala TR: Toxicity of intravesical recombinant human tumor necrosis factor in cynomolgus monkeys. J Biol Response Mod 9:445–447, 1990.
Raeth U, Schmid H, Hofman J, Wiedenmann B, Kempeni J, Schlick E, Kaufmann M: Intraperitoneal application of recombinant tumor necrosis factor as an effective palliative treatment of malignant ascites from ovarian and gastroenteropancreatic carcinomas (Abstr.). Proc Am Soc Clin Oncol 8:181–181, 1989.
Kasid A, Morecki S, Aebersold P, Cornetta K, Culver K, Freeman S, Director E, Lotze MT, Blaese RM, Anderson WF, Rosenberg SA: Human gene transfer: Characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. Proc Natl Acad Sci USA 87:473–477, 1990.
Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, Merino MJ, Culver K, Miller AD, Blaese RM, Anderson WF: Gene transfer into humans — immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323:570–578, 1990.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer Science+Business Media New York
About this chapter
Cite this chapter
Alexander, R.B. (1992). Tumor necrosis factor and chemotherapeutic drugs targeted at DNA topoisomerase II for the treatment of genitourinary malignancies. In: Lepor, H., Lawson, R.K. (eds) Therapy for Genitourinary Cancer. Cancer Treatment and Research, vol 59. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3502-7_10
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3502-7_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6553-2
Online ISBN: 978-1-4615-3502-7
eBook Packages: Springer Book Archive